2003 NIH Research Festival
<< Back < Home
Mini-Symposia Summary
Link to NIH
Link to General Schedule of Events
Link to Clinical Center 50th Anniversary Symposium
Link to Mini Symposia
Link to Poster Session
Link to Job Fair for NIH Postdoctoral Fellows
Link to Special Exhibits on NIH Intramural Resources
Link to TSA Research Festival Exhibit Show
Link to Festival Food and Music Fair
Link to Research Festival Committee
Mini-symposia Session I
Wednesday, October 15, 2003
Natcher Conference Center
Programmed Cell Death: Methods and Pathways 10:30 a.m. - 12:00 p.m.
Co-chaired by:
Richard Siegel, M.D., Ph.D.
Head, Immunoregulation Unit and Investigator, Autoimmunity Branch, NIAMS

Sponsored by the NIH Apoptosis Interest Group
Conference Room E1/E2, Natcher Conference Center
There has been an explosion of interest in studying programmed cell death in
many fields of biomedical research. Recently it has become apparent that there are
multiple pathways leading to cell death besides classical caspase-mediated
apoptosis. Receptors that signal for cell death (death receptors) may have other
non-apoptotic functions as well. Techniques for visualizing cell death signaling in
real-time in living cells has enhanced our understanding of these pathways. How
phagocytic and antigen-presenting cells recognize and respond to apoptotic cells is
also an emerging area of interest. This session will feature talks on these topics
combining new insights into these signaling pathways and novel techniques for
studying programmed cell death.
Death Receptor Signaling: Paradigms and Paradoxes
Richard Siegel, M.D., Ph.D.
Head, Immunoregulation Unit and Investigator, Autoimmunity Branch, NIAMS
Visualizing Signaling by Bcl-2 Family Proteins in vivo
Mariusz Karbowski, Ph.D.
Research Fellow, Biochemistry Section, Surgical Neurology Branch, NINDS
Caspase-independent Non-apoptotic HIV-1 Induced Cell Death in CD4+ T Cells
Diane L. Bolton
Predoctoral IRTA, Laboratory of Immunology, NIAID
Phagocytosis of Apoptotic Cells: Mechanisms and Consequences
Emily Shacter, Ph.D.
Chief, Laboratory of Biochemistry, Division of Therapeutic Proteins, CBER, FDA
    Go to the top